News | April 14, 2026
NASA’s Artemis II mission to on board Opella’s Dulcolax for lunar orbit mission
A brand from Opella will be part of the official NASA astronaut formulary
A brand from Opella will be part of the official NASA astronaut formulary
The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms
Drugmaker taps 1 million retail touchpoints, quick commerce and modern trade to expand ingredient-led skincare franchise
API maker begins circulation of second and final call money notice for partly paid-up rights shares, completing the last leg of its 2024 fundraising cycle
New adult supplement combines 26 vitamins, minerals and botanicals to address stress, energy, immunity and cognitive wellness in one daily tablet
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
The company said the increase—up to 20%—takes effect immediately, or as current contracts allow
Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
Subscribe To Our Newsletter & Stay Updated
